HI-MAG held a symposium to celebrate its 5th anniversary. A large number of guests participated in the event to collectively celebrate previous achievements in the field of health research related to obesity, metabolic, and vascular diseases.
Investigating Metabolic, Obesity and Vascular Diseases
The Helmholtz Institute for Metabolic, Obesity and Vascular Research (Helmholtz-Institut für Metabolismus-, Adipositas- und Gefäßforschung, HI-MAG), an institute from Helmholtz Munich at the…
Tirzepatide is a recently approved treatment for type-2 diabetes. Treatment with tirzepatide decreases body weight while improving glucose metabolism in patients with obesity and type-2 diabetes. Although the drug is designed to activate receptors…
During the COVID-19 pandemic, an increase in the chronic autoimmune disease type 1 diabetes was observed in children, also in Germany. Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern (KVB),…
The German Diabetes Society (DDG) awards this year's Werner Creutzfeldt Prize to Helmholtz Munich scientist PD Dr Timo Müller for his exceptional work in the research field of Incretin-based diabetes and obesity. This is already the second time in a…
Lean, metabolically unhealthy, people have a risk of cardiovascular disease (CVD) that is higher than the risk observed in obese, metabolically healthy people. Recently, novel cluster analyses (computer-based grouping of people) also identified a…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:
